Association between pioglitazone use and head and neck cancer: Population‐based case‐control study

Yang, Tzong Hann; Xirasagar, Sudha; Wu, Cheng-Shong; Kao, Yi Wei; Shia, Ben‐Chang; Lin, Herng Ching

doi:10.1002/hed.26046

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Head and neck cancers (HNC) is a major cause of cancer-related mortality in Asian. 1 With continual advancements in treatment techniques, patients with HNC may experience improved long-term survival. 2 Hence, improving the long-term quality of life of these patients is essential.…”

Section: Introductionmentioning

confidence: 99%

Vertebral and Carotid Artery Stenosis after Irradiation Both Raise Ischemic Stroke Risk in Head and Neck Cancer Patients

Jiang,

Chang,

Huang

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To study the risk of ischemic stroke (IS) following carotid (CAS) or vertebral artery stenosis (VAS) in head and neck cancer (HNC) patients after radiation therapy (RT). Methods: We included HNC patients who received RT between 2010 and 2023. They underwent regular head and neck imaging monitoring to evaluate cancer recurrence at the department of radiation-oncology and vascular examinations at the department of neurology. Patients were initially divided into nasopharyngeal carcinoma (NPC) and non-NPC groups. The primary outcome was the occurrence of IS after RT, and the secondary outcomes included the development of >50% CAS or >50% VAS after RT. Cox regression and Kaplan?Meier analyses were conducted to compare the outcomes of the study groups. Further analysis was conducted based on the presence or absence of >50% CAS or >50% VAS during the follow-up period. Results: Of the 1,423 HNC patients, 19%, 6.8%, and 2.3% developed >50% CAS, >50% VAS, and IS during a 58-month follow-up. Compared with the NPC group, the non-NPC group exhibited a higher incidence of >50% CAS (25.4% vs. 10.7%, p<0.001) and >50% VAS (8.8% vs. 4.3%, p<0.001), but similar risks of IS. In patients with HNC, >50% CAS (adjusted hazard ratio [HR]=3.21, 95% confidence interval [CI]=1.53-6.71), and >50% VAS (adjusted HR=2.89, 95% CI=1.28-6.53) were both the independent predictors of IS. In the patients with NPC, >50% CAS was an independent predictor of anterior circulation IS (adjusted HR=4.39, 95% CI=1.17-16.47). By contrast, >50% VAS emerged as a predictor of posterior circulation IS in both the NPC (adjusted HR=15.02, 95% CI=3.76-60.06) and non-NPC groups (adjusted HR=13.59, 95% CI=2.21-83.46). Conclusion: HNC patients with >50% CAS or >50% VAS after RT had an increased risk of IS within their corresponding vascular territory. CAS is a major predictor of IS in NPC patients, whereas VAS is a major predictor of IS in both NPC and non-NPC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Vertebral and Carotid Artery Stenosis after Irradiation Both Raise Ischemic Stroke Risk in Head and Neck Cancer Patients

Jiang,

Chang,

Huang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Early detection and timely treatment significantly improve the chances of successful outcomes ( 10 ). Prevention and early detection through regular dental and medical check-ups, lifestyle modifications (avoiding tobacco use and excessive alcohol consumption) and vaccination against HPV (for oropharyngeal cancers) are essential in reducing the burden of head and neck cancers ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)

Wei,

Lan,

Qiu

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Immunotherapy has become one of the most promising approaches in tumor therapy, and there are numerous associated clinical trials in China. As an immunosuppressive tumor, head and neck squamous cell carcinoma (HNSCC) carries a high mutation burden, making immune checkpoint inhibitors promising candidates in this field due to their unique mechanism of action. The present review outlines a comprehensive multidisciplinary cancer treatment approach and elaborates on how combining immunochemotherapy and immunoradiotherapy guidelines could enhance clinical efficacy in patients with HNSCC. Furthermore, the present review explores the immunology of HNSCC, current immunotherapeutic strategies to enhance antitumor activity, ongoing clinical trials and the future direction of the current immune landscape in HNSCC. Advanced-stage HNSCC presents with a poor prognosis, low survival rates and minimal improvement in patient survival trends over time. Understanding the potential of immunotherapy and ways to combine it with surgery, chemotherapy and radiotherapy confers good prospects for the management of human papillomavirus (HPV)-positive HNSCC, as well as other HPV-positive malignancies. Understanding the immune system and its effect on HNSCC progression and metastasis will help to uncover novel biomarkers for the selection of patients and to enhance the efficacy of treatments. Further research on why current immune checkpoint inhibitors and targeted drugs are only effective for some patients in the clinic is needed; therefore, further research is required to improve the overall survival of affected patients.

show abstract

Association between pioglitazone use and head and neck cancer: Population‐based case‐control study

Cited by 2 publications

References 31 publications

Vertebral and Carotid Artery Stenosis after Irradiation Both Raise Ischemic Stroke Risk in Head and Neck Cancer Patients

Vertebral and Carotid Artery Stenosis after Irradiation Both Raise Ischemic Stroke Risk in Head and Neck Cancer Patients

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)

Contact Info

Product

Resources

About